Recomendaciones de prescripción en neumonías. NICE

http://www.medicinesresources.nhs.uk/upload/documents/Health%20In%20Focus/NICEBites%20January%202015.pdf

Análisis de coste-utilidad de la telemedicina en pacientes con EPOC

http://www.ncbi.nlm.nih.gov/pubmed/25052387

http://www.ncbi.nlm.nih.gov/pubmed/25586810

Guía de práctica clínica de la enfermedad pulmonar obstructiva crónica (EPOC) ALAT-2014: Preguntas y respuestas

Enlace aquí

Guía para pacientes con CPAP

Guía para pacientes con CPAP de la SEPAR

Corticoides sistémicos en la exacerbación de la EPOC : duración del tratamiento

Una revisión Cochrane  : aquí

Authors' conclusions

Information from a new large study has increased our confidence that five days of oral corticosteroids is likely to be sufficient for treatment of adults with acute exacerbations of COPD, and this review suggests that the likelihood is low that shorter courses of systemic corticosteroids (of around five days) lead to worse outcomes than are seen with longer (10 to 14 days) courses. We graded most available evidence as moderate in quality because of imprecision; further research may have an important impact on our confidence in the estimates of effect or may change the estimates. The studies in this review did not include people with mild or moderate COPD; further studies comparing short-duration systemic corticosteroid versus conventional longer-duration systemic corticosteroid for treatment of adults with acute exacerbations of COPD are required.